Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

Surface Oncology (Nasdaq: SURF), an immuno-oncology company, announced that its CEO, Rob Ross, M.D., will participate in a Novel Immuno-Oncology panel at the Cowen 43rd Annual Health Care Conference in Boston, MA, on March 6, 2023, at 9:10 a.m. ET. This session will focus on the company’s innovative therapies targeting the tumor microenvironment. A live audio webcast will be accessible on the Surface Oncology website, with a replay available afterward. The company is developing next-generation antibody therapies, including SRF388 and SRF114, and has collaborations with Novartis and GlaxoSmithKline.

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a Novel Immuno-Oncology (IO) panel discussion at the Cowen 43rd Annual Health Care Conference taking place at the Marriott Copley Place in Boston, MA. 

The panel discussion will be held on Monday, March 6, 2023, at 9:10 a.m. ET, and a live audio webcast of the session may be accessed by visiting the Events page on the Investors & Media section of the Surface Oncology website. In addition, a replay of the webcast will be available following the discussion.

About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned programs; SRF388, a Phase 2 program which targets IL-27, and SRF114, a Phase 1 program which selectively depletes regulatory T cells in the tumor microenvironment via targeting CCR8. In addition, Surface has two partnerships with major pharmaceutical companies; a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com

FAQ

What is the date and time of Surface Oncology's panel discussion?

The panel discussion is scheduled for March 6, 2023, at 9:10 a.m. ET.

Who will represent Surface Oncology at the Cowen 43rd Annual Health Care Conference?

Rob Ross, M.D., the CEO of Surface Oncology, will participate in the panel discussion.

Where can I access the webcast of the Surface Oncology panel?

The live audio webcast can be accessed on the Events page of the Investors & Media section of the Surface Oncology website.

What are the main programs developed by Surface Oncology?

Surface Oncology is developing SRF388, a Phase 2 program targeting IL-27, and SRF114, a Phase 1 program that targets CCR8 to deplete regulatory T cells.

What collaborations does Surface Oncology have with other pharmaceutical companies?

Surface has collaborations with Novartis for targeting CD73 and with GlaxoSmithKline targeting PVRIG.